Putative peptide neurotransmitters in human neuropathology: a review of topography and clinical implications.
In Huntington's disease, there is a decrease of the neuropeptides, substance P, enkephalins, and cholecystokinin in the striatonigral system, whereas in Parkinson's disease an increase of substance P is found in the substantia nigra. Several neuropeptides should be involved in Alzheimer's disease: substance P, endorphins, vasopressin, ACTH, somatostatin, vasoactive intestinal peptide, cholecystokinin, neurotensin, delta sleep-inducing peptide. Alterations of substance P, vasoactive intestinal peptide, cholecystokinin, somatostatin, and endorphins may be related to the pathophysiology of schizophrenia. Delta sleep-inducing peptide may interfere in addiction pathology.
D000544:Alzheimer Disease / Q000378:metabolism; D001931:Brain Mapping; D002493:Central Nervous System Diseases / Q000378:metabolism*; D002766:Cholecystokinin / Q000502:physiology; D004745:Enkephalins / Q000502:physiology; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism; D008032:Limbic System / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000502:physiology*; D018377:Neurotransmitter Agents / Q000502:physiology*; D010300:Parkinson Disease / Q000378:metabolism; D012559:Schizophrenia / Q000378:metabolism; D013373:Substance P / Q000502:physiology; D019966:Substance-Related Disorders / Q000378:metabolism
D004745:Enkephalins; D009419:Nerve Tissue Proteins; D018377:Neurotransmitter Agents; D013373:Substance P; D002766:Cholecystokinin